Esperion Gets $33M To Continue Work On Cholesterol Buster

April 25, 2013 8:35 PM

46 0

ANN ARBOR — Esperion Therapeutics Inc. announced that it has completed a $33 million preferred stock financing led by new investor Longitude Capital.

Esperion is developing and commercializing new therapies to treat high cholesterol that can be taken in pill form, and which don’t cause some of the side effects of current statin drugs.

Read more

To category page